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Abstract
Guillain-Barre syndrome (GBS) is a serious neurological disorder associated with a 
rapid progressive ascending muscle paralysis, and it is the most common neurological 
autoimmune disorder that affects the peripheral nervous system, which is usually trig-
gered by viral or bacterial infection. GBS is rare in children and characterized by rapid 
progressive onset ascending muscle weakness associated with pain and sensory dysfunc-
tion. Miller Fisher syndrome (MFS), a variant of GBS, is rare in pediatric population 
which is typically manifested by ataxic gait, ophthalmoplegia, and areflexia since it is 
rare in children. It is vitally important to early diagnose this condition and to initiate 
early treatment to prevent further complications and long-term morbidity. Since the 
outbreak of Zika virus, the incidence of GBS has been increased. Zika virus associated 
with autoimmune anti-ganglioside antibodies trigger which lead to GBS development. 
Zika virus infection should be strongly considered in patients who present with classical 
signs of Miller Fisher syndrome, especially travelers and residents from endemic areas.
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1. Introduction
1.1 History
In 1916, two French Neurologists Georges Charles Guillain and Jean Alexandre 
Barre and French Physiologist Andre Strohl reported an original paper encountered 
new syndrome in two soldiers with muscle weakness, absence of deep tendon 
reflexes and sensory impairment and described the key diagnosis of albumin-
cytologic disassociation in the cerebrospinal fluid along with changes in electromy-
ography and nerve conduction studies. Both patients were managed with massage 
therapy and Strychnine injection and showed clinical recovery after few months [1].
GBS is rare but the commonest cause for acute ascending paralytic polyne-
phropathy. GBS is considered to be an acute immune-mediated disorder that causes 
peripheral polyneuropathy. Most cases of GBS are preceded by either viral or bacte-
rial infection, which triggers the immune system affecting the peripheral nervous 
system causing a rapid progressive demyelinating polyneuropathy [2, 3].
The incidence of GBS has been increased since the outbreak of certain infections 
such as Zika virus epidemic in Latin America in 2015. GBS is the most leading cause 
of acute ascending muscle paralysis with an annual incidence of 1–2 per 100,000 
persons per year worldwide. GBS is more common in males than females [2, 3].
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GBS is a rapid demyelinating peripheral neuropathy that typically manifest as 
ascending muscle weakness that is symmetric in nature associated with reduced 
or absent deep tendon reflexes. GBS has been also associated with pain along with 
sensory impairment [4].
GBS is an acute immune-mediated demyelinating polyneuropathy and it is the 
commonest cause of acute muscle paralysis in pediatric age group patients [5, 6].
MFS is a rare neurological disorder which was initially recognized in 1932 by 
James Collier as a classical triad of ophthalmoplegia, ataxia and absent deep tendon 
reflexes. Later in 1956 Charles Miller Fisher a Canadian Neurologist described and 
reported details isolated clinical entity of three patients who presented with oph-
thalmoplegia, ataxia and areflexia [7].
MFS has an annual incidence of 0.9 per 1000,000 populations and affect males 
more than females at ratio of 2:1 and commonly affect Asian population especially 
at their fourth decade of life [7].
MFS most commonly preceded by Campylobacter jejuni infection and has strong 
association with positive anti-GQ1b antibodies [7].
Zika virus infection has been associated with different neurological disorders 
such as microcephaly and since the initial outbreak of Zika virus infection the 
number of GBS cases has been increased in endemic countries [8].
2. Pathophysiology and immunopathology
The neurological symptoms and signs of GBS usually take place 4 weeks 
after the initial respiratory or gastrointestinal infection which account for about 
Figure 1. 
Basic structure of motor neuron [10].
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two-third of GBS cases in adult population. The immune system will be stimulated 
secondary to infectious antigen with Campylobacter jejuni (C. jejuni) being the most 
common infectious pathogenic agent which account for 25–50% of adult GBS cases 
[9]. These infectious antigens cause stimulation of both cellular and hormonal 
systems leading to axonal damage and demyelination of the peripheral nerve and 
nerve roots (Figure 1) [11].
Monocytes, T-cells, especially CD4+ T-helper cells and B-cells in order of 
frequency, have been commonly implicated in the immunopathology of GBS 
cases especially in the acute inflammatory demyelinating polyradiculoneuropathy 
(AIDP) [11].
More than 80% of the patients with Miller Fisher syndrome have anti-GQ1b IgG 
antibodies which mainly activate the compliment system especially at the presyn-
aptic nerve ending and perisynaptic Schwann cells which has been implicated in the 
pathogenesis of MFS [11, 12].
3. Clinical features
GBS is a rapid inflammatory ascending symmetric muscle weakness associated 
with reduced or complete absent of deep tendon reflexes. The most common symp-
tom is inability to walk. The frequent findings on the clinical examination include 
hyperesthesia, autonomic dysfunction, sensory loss, ataxia, bilateral facial nerve 
palsy and third cranial nerve palsy [4, 13].
3.1 Clinical subtypes of Guillain-Barre syndrome (GBS)
A number of clinical subtypes of Guillain-Barre Syndrome (GBS) are identified.
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) is con-
sidered to be the most common subtype and account for approximately of 90 
percent of GBS patients in the Unites States. Patients with this subtype typically 
present with progressive ascending symmetric muscle weakness and areflexia 
associated with severe pain and autonomic dysfunction such as fluctuation in 
blood pressure, urinary incontinence or syncope. This clinical subtype typically 
shows a slow nerve conduction velocity with no clear anti-ganglioside antibodies 
association [14].
Other subtype of GBS is the acute motor axonal neuropathy (AMAN) that 
accounts for 5% of Guillain-Barre syndrome (GBS) patients in United States. This 
subtype purely presents with motor weakness without sensory symptoms. Nerve 
conduction study shows axonal polyneuropathy with normal sensory nerve action 
potential. Patients with acute motor axonal motor neuropathy have strong associa-
tion with Campylobacter jejuni (C. jejuni) infection with positive antibodies against 
gangliosides GM1, GD1a, GaINac-GD1a and GD1b [14].
The acute motor-sensory axonal neuropathy (AMSAN) is a rare and severe 
variant of GBS [15], which has similar clinical features to acute motor axonal neu-
ropathy but with predominantly sensory loss and positive antibodies against GM1 
and GD1a. Nerve conduction study showed axonal polyneuropathy with reduced or 
absent sensory nerve action potential [14].
The pharyngeal-cervical brachial syndrome (PCB) is another rare subtype of 
GBS [16]. Patient with PCB syndrome typically present with rapid and progressive 
oropharyngeal and shoulder muscle weakness associated with absent deep tendon 
reflexes in the upper limbs. The nerve conduction study in patients with PCB syn-
drome is generally normal but sometimes showed axonal neuropathy in the arms. 
PCB syndrome associated with positive IgG anti-GT1a antibodies [17].
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Miller Fisher syndrome is one of the GBS variant. It is an uncommon neuro-
logical disorder which account of about 5% of GBS cases. Patients with Miller 
Fisher syndrome typically present with clinical trial of ophthalmoplegia which is 
bilateral symmetric in most patients, ataxia and absent deep tendon reflexes. The 
commonest initial presenting symptoms in patients with Miller Fisher syndrome 
is diplopia (double vision) which is due to acute onset-ophthalmoplegia. Other 
less frequent signs and symptoms of MFS include headache, difficulty swallowing 
and photophobia (Table 1). MFS is an immune-mediated neurological disorder 
and more than 80% of patients with MFS showed positive IgG anti-GQ1b anti-
bodies. Electrophysiological findings in patients with MFS commonly showed 
reduced sensory nerve action potentials and absent H reflexes (Figure 2 and 
Table 2) [7, 12, 18].
Bickerstaff brainstem encephalitis currently considered to be another variant of 
Fisher syndrome associated with central nervous system involvement. Patients with 
Bickerstaff brainstem encephalitis typically present with ophthalmoplegia, ataxia, 
hyperreflexia and altered sensorium [19].
Bickerstaff brainstem encephalitis is an immune-mediated neurological disorder 
usually preceded by infection and associated with positive anti-GQ1b antibodies [19].
Figure 2. 
Percentage of different subtypes of GBS [14, 18].
• Double vision (diplopia): most common
• Abnormal gait (ataxia)
• Less frequent symptoms
• Headache
• Difficulty swallowing (dysphagia)
• Light intolerance (photophobia)
Table 1. 
Clinical symptoms associated with MFS.
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Zika virus belongs to the virus family Flaviviridae. This virus was first isolated 
in 1947 from a monkey in the Zika forest of Uganda. Zika virus spread mainly by 
Aedes mosquitos as well as by intrauterine transmission, blood and sexual inter-
course [20]. Most cases of Zika virus infection are associated with mild symptoms 
such as fever, headache, maculopapular skin rash, red eyes (conjunctivitis) and 
joint or muscle pain [21–23].
The outbreak of Zika virus infection in Brazil in 2015 has been associated with a 
more serious neurological complication such as Guillain-Barre syndrome [24]. This 
outbreak has been also resulted in increase in the incidence of babies with micro-
cephaly [25, 26].
During Zika outbreak in Brazil, patients who developed Guillain-Barre syn-
drome secondary to Zika virus infection were found to have a higher level of anti-
ganglioside antibodies of both IgM and IgG isotypes as compared to other patients 
with Zika infection in the absence of GBS [27].
Since Zika virus associated with serious devastating neurological complica-
tions such as Guillain-Barre syndrome and congenital anomalies in the newborn 
babies, several methods have been developed in order to detect the virus in early 
course of infection. Nonstructural protein 1 (NS1) is considered to be an essential 
biomarker for early detection and diagnosis of Zika virus. The development of 
double-antibody sandwich ELISA (DAS-ELISA) has been also used for early and 
rapid detection of ZIKA-NS1 protein in patients who newly infected with Zika 
virus [28].
At the present time, there is no antiviral treatment or specific vaccines approved 
for patients infected with Zika virus. Supportive care remains the main modality 
of managing these patients, yet the challenge remains to prevent congenital Zika 
syndrome in pregnant women [29].
Type Clinical symptoms Electrophysiological 
findings
Serological tests
Acute inflammatory 
demyelinating 
polyradiculoneuropathy
Muscle weakness 
with sensory 
and autonomic 
dysfunction
Slow nerve conduction 
velocity
No clear anti-ganglioside 
antibodies association
Acute motor axonal 
neuropathy
Muscle weakness 
with no sensory 
impairment
Axonal 
polyneuropathy with 
normal sensory nerve 
action potential
Positive anti-ganglioside 
antibodies GM1, GD1a, 
GaINac-GD1a, and 
GD1b
Acute motor-sensory 
axonal neuropathy
Muscle weakness 
with sensory 
involvement
Axonal 
polyneuropathy with 
absent or reduced 
sensory nerve action 
potential
Positive antibodies 
against GM1 and GD1a
Pharyngeal-cervical 
brachial variant
Oropharyngeal and 
shoulder muscle 
weakness
Generally normal, 
occasional axonal 
neuropathy in the 
arms
Positive IgG anti-GT1a 
antibodies
Miller Fisher syndrome Ophthalmoplegia, 
ataxia and areflexia
Reduced sensory nerve 
action potential and 
absent H-reflexes
Positive IgG anti-GQ1b 
antibodies
Table 2. 
Summary of the clinical subtypes of Guillain-Barre syndrome.
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4. Diagnosis of Guillain-Barre syndrome and Miller Fisher variant
The diagnosis of GBS and Miller Fisher variant is often made clinically based on 
the symptoms and clinical signs of the patients [30]. A more detail and supporting 
investigational studies such cerebrospinal fluid (CSF) analysis, electrophysiological 
tests such as nerve conduction studies, ultrasonographic and MRI imaging along 
with serologic testing can be carried out to confirm the diagnosis of GBS and other 
variants such as MFS [31].
Electrophysiological findings in patients with GBS suggestive of demyelination 
process in the form of reduce motor conduction velocity (MCV), prolonged motor 
distal latency and increase F wave latency. The findings of conduction block with 
absent H-reflex are considered to be the commonest and early sign in GBS [32].
Patients with Fisher-Bickerstaff syndrome (FBS) typically showed sensory 
axonal neuropathy in the form of reduced sensory nerve action potential (SNAP) 
amplitude in the absence of demyelination parameters [33].
The use of imaging studies such as peripheral nerve ultrasound and MRI are 
helpful diagnostic tools to diagnose inflammatory peripheral nerve roots [34].
The findings of MRI findings in patients with Miller-Fisher syndrome can range 
from cranial nerve involvement especially the optic nerve to severe cerebral white 
matter lesions [35, 36].
Another important biomarker which help confirming the diagnosis of GBS is the 
cerebrospinal fluid (CSF) analysis which typically show albuminocytologic disso-
ciation (elevated protein level with normal cell count in cerebrospinal fluid) which 
has been also seen in patients with MFS and Bickerstaff brainstem encephalitis [37].
Although the diagnosis of MFS is based mainly on the classical trial of ophthal-
moplegia, areflexia and ataxia which developed approximately within 1 week to 10 
days after the initial infection, serologic tests can be used to confirm the diagnosis. 
The presence of anti-GQ1b antibodies, which was first described in 1992, provides a 
strong diagnostic marker for MFS [38].
The yield of this serological marker is high if the test done within 4 weeks after 
initial clinical onset [39].
5.  Treatment practice of Guillain-Barre syndrome and Miller Fisher 
variant
Since GBS is a demyelinating polyneuropathy that cause rapid ascending muscle 
paralysis it is vitally important to admit patients with GBS to the intensive care 
unit for close monitoring and observation as over 30% of GBS patients can develop 
respiratory failure [40].
Currently plasmapheresis and intravenous immunoglobulin (IVIG) are the only 
effective therapies for GBS [41].
The timing of plasmapheresis has a significant impact on the clinical outcome if it 
is done within 2 weeks from the initial clinical onset as it reduces the time needed for 
ventilator support and improves motor function and walking without any help. The 
use of IVIG also shown to yield a good response in patients with GBS, however the 
use of plasmapheresis and IVIG were equally effective in GBS patients and combined 
therapy showed no significant difference in the final patients’ clinical outcomes 
as compared to a single therapy. There is no role of corticosteroids therapy in the 
management of GBS even if it is used in high dose in the initial phase of GBS [40].
In patients with MFS IVIG have shown to speed the recovery of ophthalmoplegia 
and ataxia. However, IVIG and plasmapheresis have no significant impact on the 
overall outcome in patients with Miller Fisher syndrome [42].
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6. Prognosis of Guillain-Barre syndrome and Miller Fisher variant
The overall prognosis of GBS is positive. Not all patients with GBS show com-
plete recovery; however, most of these patients have a good outcome on one year 
follow up [43].
However, factors that indicate poor prognosis in GBS patients include old age 
and severe neurological deficit with cranial nerve injury at clinical onset, the need 
for mechanical ventilation and axonal damage in the nerve conduction study 
(Table 3) [44].
MFS has an overall a good prognosis [45], and despite the fact it has self-limiting 
course in most cases, Miller Fisher rarely progressive to respiratory failure [46].
The early diagnosis of MFS and early treatment with plasma exchange or 
intravenous immunoglobulins can reduce the severity of the disease and hasten the 
recovery in patients with MFS [46].
The ataxia and ophthalmoplegia usually recover within 1 to 3 months after 
initial clinical onset with almost complete resolution within 6 months. The loss of 
deep tendon reflexes may persist however does not interfere with daily functional 
activities [47].
7. Conclusion
Guillain-Barre syndrome is a serious neurological disorder associated with a 
rapid progressive ascending muscle paralysis. It is essential to provide maximum 
supportive medical care and start early therapy to prevent further deterioration and 
improve the future outcome of the patients.
Miller Fisher is a variant of Guillain-Barre syndrome is rare in pediatric popula-
tion with an overall good prognosis. Early recognition and management of such 
uncommon neurological disorder will help in preventing further complications and 
long-term morbidity.
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Abbreviations
GBS Guillain-Barre syndrome
MFS Miller Fisher syndrome
PCB pharyngeal-cervical brachial
MRI magnetic resonance imaging
IVIG intravenous immunoglobulin
ELISA enzyme-linked immunosorbent assay
1. Elderly patients
2. Severe focal neurological deficit at the initial presentation
3. Mechanical ventilation
4. Axonal demyelination in nerve conduction study
Table 3. 
Poor prognostic factors in GBS [44].
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